NR1H4 and metabolic dysfunction-associated steatohepatitis: Based on this knowledge, BA signaling pathways acting through the FXR/NR1H4 or Takeda G protein-coupled receptor 5 (TGR5/G protein-coupled BA receptor 1) have been identified as potential targets for NAFLD/NASH treatment (5).